Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder

Journal of Affective Disorders

Volumn 100, Issue SUPPL. 1, 2007, Pages

  Adler, Caleb M ^a   Fleck, David E ^a   Brecher, Martin ^b   Strakowski, Stephen M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bipolar disorder; Dose; Efficacy; Mania; Quetiapine; Tolerability

Indexed keywords

LITHIUM; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM;

AKATHISIA; ARTICLE; BARNES AKATHISIA RATING SCALE; BIPOLAR MANIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MANIA; META ANALYSIS; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RATING SCALE; SIDE EFFECT; SIMPSON ANGUS SCALE; SOMNOLENCE; SYSTEMATIC REVIEW; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 34249302711     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2007.02.004     Document Type: Article

References (52)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159 4 Suppl (2002) 1-50
2. Arvanitis L.A., and Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry 42 4 (1997) 233-246
3. AstraZeneca Pharmaceuticals LP. Data on File (2005)
4. AstraZeneca Pharmaceuticals LP, 2005b. SEROQUEL® (quetiapine fumarate) tablets - Prescribing Information.
5. Ayuso-Gutierrez J.L., and del Rio Vega J.M. Factors influencing relapse in the long-term course of schizophrenia. Schizophr. Res. 28 2-3 (1997) 199-206
6. Bobes J., Garc A.P.M.P., et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J. Sex Marital Ther. 29 2 (2003) 125-147
7. Bowden C., Grunze H., et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry 66 1 (2005) 111-121
8. Buckley P.F. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr. Med. Res. Opin. 20 9 (2004) 1357-1363
9. Cheer S.M., and Wagstaff A.J. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 18 3 (2004) 173-199
10. DelBello M.P., Schwiers M.L., et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J. Am. Acad. Child Adolesc. Psych. 41 10 (2002) 1216-1223
11. Gaebel W., Moller H.J., et al. Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254 2 (2004) 129-140
12. Ghaemi S.N., Goldberg J.F., et al. Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study [abstract]. Bipolar Disord. 5 suppl 1 (2003) 50
13. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 17 2 (2003) 149-173 (discussion 147)
14. Grunze H., Kasper S., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J. Biol. Psychiatry 3 3 (2002) 115-124
15. Grunze H., Kasper S., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders, Part II: Treatment of mania. World J. Biol. Psychiatry 4 1 (2003) 5-13
16. Gupta S. Safety in treating bipolar disorder. J. Fam. Pract. (2003) S26-S29 (Suppl)
17. Hirschfeld R.M., Calabrese J.R., et al. Screening for bipolar disorder in the community. J. Clin. Psychiatry 64 1 (2003) 53-59
18. Kane J.M. Tardive dyskinesia in affective disorders. J. Clin. Psychiatry 60 Suppl 5 (1999) 43-47 (discussion 48-9)
19. Kane J.M. Extrapyramidal side effects are unacceptable. Eur. Neuropsychopharmacol. 11 suppl 4 (2001) S397-S403
20. Keck Jr. P.E., McElroy S.L., et al. Factors associated with pharmacologic noncompliance in patients with mania. J. Clin. Psychiatry 57 7 (1996) 292-297
21. Keck Jr. P.E., Marcus R., et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160 9 (2003) 1651-1658
22. Keck Jr. P.E., Versiani M., et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry 160 4 (2003) 741-748
23. Ketter T.A., Wang P.W., et al. Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia?. J. Psychiatr. Res. 38 1 (2004) 47-61
24. Ketter T.A., Jones M., et al. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. J. Affect. Disord. 100 (2007) S45-S53 10.1016/j.jad.2007.02.006
25. Khanna S., Vieta E., et al. Risperidone monotherapy in acute bipolar mania (abstract P108). Bipolar Disord. 5 Suppl 1 (2003) 60
26. Korn M. Schizophrenia and bipolar disorder: an evolving interface. Medscape Psychiatr. Ment. Health 9 2 (2004)
27. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr. Scand., Suppl. 380 (1994) 8-13
28. Masand P.S., Fazal F.S., et al. Safety considerations in pharmacotherapy of bipolar disorder. CNS Spectr. 9 11 Suppl 12 (2004) 16-26
29. McIntyre R.S., Brecher M., et al. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. 15 5 (2005) 573-585
30. McIntyre R.S., Jones M., et al. Quetiapine in the treatment of acute bipolar mani: Efficacy aross a broad range of symptoms. J. Affect. Disord. 100 (2007) S5-S14 10.1016/j.jad.2007.02.007
31. Mintzer J.E., Mullen J.A., et al. A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr. Med. Res. Opin. 20 9 (2004) 1483-1491
32. O'Keefe C., and Noordsy D. Reversal of weight gain associated with antipsychotic treatment. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA (2001)
33. Sachs G.S., Grossman F., et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry 159 7 (2002) 1146-1154
34. Sachs G., Chengappa K.N.R., et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 6 3 (2004) 213-223
35. Schlechte J.A. Clinical impact of hyperprolactinaemia. Bailliere's Clin. Endocrinol. Metab. 9 2 (1995) 359-366
36. Seeman P., and Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry 3 2 (1998) 123-134
37. Stanniland C., and Taylor D. Tolerability of atypical antipsychotics. Drug Saf. 22 3 (2000) 195-214
38. Strakowski S.M., DelBello M.P., et al. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 15 9 (2001) 701-718
39. Strakowski S.M., Del Bello M.P., et al. Atypical antipsychotics in the treatment of bipolar disorder. Expert Opin. Pharmacother. 4 5 (2003) 751-760
40. Suppes T., McElroy S., et al. Use of quetiapine in bipolar disorder: a case series with prospective evaluation. Int. Clin. Psychopharmacol. 19 (2004) 173-174
41. Suppes T., Dennehy E.B., et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66 7 (2005) 870-886
42. Sussman N. The implications of weight changes with antipsychotic treatment. J. Clin. Psychopharmacol. 23 3 Suppl 1 (2003) S21-S26
43. Sussman N., Mullen J., et al. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. J. Affect. Disord. 100 (2007) S55-S63 10.1016/j.jad.2007.02.008
44. Tandon R., and Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann. Clin. Psychiatry 14 2 (2002) 123-129
45. Tohen M., Sanger T.M., et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry 156 5 (1999) 702-709
46. Tohen M., Jacobs T.G., et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch. Gen. Psychiatry 57 9 (2000) 841-849
47. Vieta E., Mullen J., et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr. Med. Res. Opin. 21 6 (2005) 923-934
48. Vieta E., Goldberg J.F., et al. Quetiapine in the treatment of acute mania: Target dose for efficacious treatment. J. Affect. Disord. 100 (2007) S23-S31 10.1016/j.jad.2007.02.009
49. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 24 1 (2001) 59-73
50. Wolf M.E., DeWolfe A.S., et al. Risk factors for tardive dyskinesia according to primary psychiatric diagnosis. Hillside J. Clin. Psychiatry 9 1 (1987) 3-11
51. Yatham L.N., Paulsson B., et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacol. 24 6 (2004) 599-606
52. Zarate Jr. C.A. Antipsychotic drug side effect issues in bipolar manic patients. J. Clin. Psychiatry 61 suppl 8 (2000) 52-61